Trial Profile

Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baltaleucel-T (Primary)
Indications Epstein-Barr virus infections; Hodgkin's disease; Leiomyosarcoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Non-Hodgkin's lymphoma
Focus Adverse reactions
Acronyms MALTED

Most Recent Events

05 Feb 2020 Status changed from active, no longer recruiting to completed.
03 Feb 2016 Planned End Date changed from 1 Feb 2021 to 1 Feb 2020 as per ClinicalTrials.gov record.
03 Feb 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com